Evoke Wealth’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$551K Sell
3,604
-181
-5% -$27.7K 0.01% 388
2025
Q4
$522K Buy
3,785
+1,002
+36% +$131K 0.01% 380
2025
Q3
$357K Buy
2,783
+109
+4% +$13.3K 0.01% 460
2025
Q2
$324K Buy
2,674
+835
+45% +$94.1K 0.01% 441
2025
Q1
$212K Buy
+1,839
New +$196K 0.01% 411
2024
Q4
Sell
-1,802
Closed -$207K 452
2024
Q3
$207K Buy
+1,802
New +$204K 0.01% 388
2022
Q4
Sell
-2,782
Closed -$211K 874
2022
Q3
$211K Buy
2,782
+890
+47% +$73.8K 0.01% 313
2022
Q2
$160K Buy
1,892
+446
+31% +$39.1K 0.01% 343
2022
Q1
$127K Hold
1,446
﹤0.01% 403
2021
Q4
$126K Sell
1,446
-134
-8% -$11.1K ﹤0.01% 415
2021
Q3
$129K Buy
1,580
+59
+4% +$5.31K ﹤0.01% 393
2021
Q2
$139K Hold
1,521
0.01% 401
2021
Q1
$130K Buy
1,521
+1,116
+276% +$100K 0.01% 354
2020
Q4
$38K Sell
405
-560
-58% -$48.9K ﹤0.01% 404
2020
Q3
$84K Buy
965
+558
+137% +$48.3K 0.01% 303
2020
Q2
$36K Sell
407
-142
-26% -$12.3K ﹤0.01% 389
2020
Q1
$45.3K Sell
549
-1,740
-76% -$155K 0.01% 350
2019
Q4
$217K Buy
2,289
+223
+11% +$20K 0.03% 213
2019
Q3
$180K Buy
+2,066
New +$186K 0.02% 273

Other funds holding NVS

Evoke Wealth's NVS Position: Q1 2026 in Review

Evoke Wealth reduced its Novartis (NVS) stake by 4.8% in Q1 2026, selling an estimated $27.7K and leaving 3,604 shares worth $551K. The position accounts for 0.01% of the portfolio, ranked #388.

Evoke Wealth first reported a position in NVS in Q3 2019 and has held it in 19 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Evoke Wealth held 3,604 shares of Novartis worth $551K as of Q1 2026.
  • Evoke Wealth sold 181 Novartis shares in Q1 2026, an estimated $27.7K.
  • Novartis made up 0.01% of Evoke Wealth's portfolio in Q1 2026, its #388 holding.
  • Evoke Wealth first reported a position in Novartis in Q3 2019 and has held it in 19 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.